Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nanatinostat + valganciclovir
- Development stage
- Unknown
- Lead developer
- Viracta Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Nanatinostat + valganciclovir is an investigational, orally administered combination therapy targeting Epstein-Barr virus (EBV)-associated malignancies. Nanatinostat is a class I-selective histone deacetylase inhibitor that induces the expression of lytic EBV proteins, notably BGLF4 protein kinase and thymidine kinase, in EBV-positive tumor cells. This activation sensitizes the tumor cells to antiviral agents by enabling phosphorylation and activation of ganciclovir or its prodrug, valganciclovir. Once activated, phosphorylated ganciclovir incorporates into cellular DNA during replication, causing chain termination and apoptosis of infected cells. The combination has shown promising activity in relapsed/refractory EBV-positive lymphomas and peripheral T-cell lymphoma (PTCL), with orphan drug designations for several rare lymphoma subtypes[1][3][5][8]. Nanatinostat was originally developed by Chroma Therapeutics; current development is led by Viracta Therapeutics.
- Brand names
- Nana-val
- Other names
- nanatinostat + valganciclovir
02
Targets
BALF5 (Epstein-Barr virus DNA polymerase)HDAC1 (Histone Deacetylase 1)
Beyond the preview
Go deeper on nanatinostat + valganciclovir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nanatinostat + valganciclovir.